BACKGROUND: The challenge of early tuberculosis (TB) infection among rural patients accessing highly active antiretroviral therapy (HAART) in a resource-limited setting with high HIV and TB burden has not been fully quantified. METHODS: This is a retrospective study nested within a prospective study of 969 patients consecutively initiated onto HAART at the CAPRISA AIDS Treatment programme in rural KwaZulu-Natal between January 2007 and December 2010. Patients were screened for clinical symptoms consistent with TB using a standardized checklist, and routine clinical investigations that included sputum microscopy and chest x-ray diagnosis. RESULTS: Of 969 HIV-infected patients initiated on HAART, 173 [17.9%; 95% confidence interval (CI): 15.5 to 20.4] had active TB at HAART initiation. TB incidence rates were 3-fold higher in the first 3 months (early incident TB) after HAART initiation [11.5/100 person-years (py); 95% CI: 7.1 to 17.5] compared with 4-24 months (late incident TB) post-HAART initiation (3.2/100 py; 95% CI: 2.2 to 4.5; incidence rate ratio: 3.6; 95% CI: 2.0 to 6.4; P < 0.001). Immune status of patients at HAART initiation did not impact TB incidence rates in patients with CD4 counts of <50 (5.3/100) and >200 (4.9/100 py; P = 0.81) cells per cubic millimeter. CD4 count gains achieved 12 months post-HAART initiation were significantly different in patients with early incident TB versus late incident TB; P = 0.03. CONCLUSIONS: Rural HIV treatment programmes in TB-endemic settings experience high rates of TB irrespective of immunologic status of patients at HAART initiation, or duration on HAART.
BACKGROUND: The challenge of early tuberculosis (TB) infection among rural patients accessing highly active antiretroviral therapy (HAART) in a resource-limited setting with high HIV and TB burden has not been fully quantified. METHODS: This is a retrospective study nested within a prospective study of 969 patients consecutively initiated onto HAART at the CAPRISA AIDS Treatment programme in rural KwaZulu-Natal between January 2007 and December 2010. Patients were screened for clinical symptoms consistent with TB using a standardized checklist, and routine clinical investigations that included sputum microscopy and chest x-ray diagnosis. RESULTS: Of 969 HIV-infectedpatients initiated on HAART, 173 [17.9%; 95% confidence interval (CI): 15.5 to 20.4] had active TB at HAART initiation. TB incidence rates were 3-fold higher in the first 3 months (early incident TB) after HAART initiation [11.5/100 person-years (py); 95% CI: 7.1 to 17.5] compared with 4-24 months (late incident TB) post-HAART initiation (3.2/100 py; 95% CI: 2.2 to 4.5; incidence rate ratio: 3.6; 95% CI: 2.0 to 6.4; P < 0.001). Immune status of patients at HAART initiation did not impact TB incidence rates in patients with CD4 counts of <50 (5.3/100) and >200 (4.9/100 py; P = 0.81) cells per cubic millimeter. CD4 count gains achieved 12 months post-HAART initiation were significantly different in patients with early incident TB versus late incident TB; P = 0.03. CONCLUSIONS:Rural HIV treatment programmes in TB-endemic settings experience high rates of TB irrespective of immunologic status of patients at HAART initiation, or duration on HAART.
Authors: Guilherme Santoro-Lopes; Ana Maria Felix de Pinho; Lee H Harrison; Mauro Schechter Journal: Clin Infect Dis Date: 2002-01-07 Impact factor: 9.079
Authors: David M Moore; Ross Harris; Viviane Lima; Bob Hogg; Margaret May; Benita Yip; Amy Justice; Amanda Mocroft; Peter Reiss; Fiona Lampe; Geneviève Chêne; Dominique Costagliola; Luigia Elzi; Michael J Mugavero; Antonella D'Arminio Monforte; Caroline Sabin; Daniel Podzamczer; Gerd Fätkenheuer; Schlomo Staszewski; John Gill; Jonathan A C Sterne Journal: J Acquir Immune Defic Syndr Date: 2009-11-01 Impact factor: 3.731
Authors: Keren Middelkoop; Linda-Gail Bekker; Landon Myer; Andrew Whitelaw; Alison Grant; Gilla Kaplan; James McIntyre; Robin Wood Journal: Am J Respir Crit Care Med Date: 2010-06-17 Impact factor: 21.405
Authors: Benjamin H Chi; Mark Giganti; Priscilla L Mulenga; Mohammed Limbada; Stewart E Reid; Wilbroad Mutale; Jeffrey S A Stringer Journal: J Acquir Immune Defic Syndr Date: 2009-09-01 Impact factor: 3.731
Authors: William Worodria; Marguerite Massinga-Loembe; Harriet Mayanja-Kizza; Jane Namaganda; Andrew Kambugu; Yukari C Manabe; Luc Kestens; Robert Colebunders Journal: Clin Dev Immunol Date: 2010-12-08
Authors: Kristen M Little; Reginah Msandiwa; Neil Martinson; Jonathan Golub; Richard Chaisson; David Dowdy Journal: BMC Infect Dis Date: 2018-07-04 Impact factor: 3.090